Raising the Index of Suspicion in Primary Care: Improving Referral Rates, Diagnosis, and Outcomes in Pulmonary Hypertension




Pulmonary Arterial Hypertension (PAH) poses a challenge for clinical practice due to delayed diagnosis and suboptimal treatment and management. As a result, patients with PAH report a poor quality of life and are associated with a huge healthcare burden. Given the complexities of screening, diagnosis and treatment of PAH, a multidisciplinary approach is critical to improving outcomes for patients, and the role of the nurse practitioner (NP) has become all the more pivotal.

This program will utilize integrated case studies to illustrate the journey of a patient with PAH to facilitate early recognition and diagnosis. The program will provide guidance on updated approaches for diagnosis and distinguishing PAH from other disorders with similar presentations. Experts will clarify the utility of available and emerging therapies for PAH and provide recommendations to design patient-centered treatment plans and ensure patient satisfaction with treatment that will aim to improve quality of life.



Vallerie V. McLaughlin, MD
Kim A. Eagle, MD Endowed Professor of Cardiovascular Medicine
Director of the Pulmonary Hypertension Program
University of Michigan
Ann Arbor, Michigan


Martha Kingman, DNP, FNP-C
Doctor of Nursing Practice
Pulmonary Hypertension Program
University of Texas Southwestern Medical Center
Dallas, Texas


Release date: May 26, 2021
Expiration date: May 26, 2022
Estimated time to complete activity: 1 hour



This educational initiative has been designed for nurse practitioners, physician assistants, and physicians who practice in primary care and specialty settings.


Upon completion of this educational activity, participants should be able to:

  • Recognize the role for the NP to improve patient outcomes in PAH
  • Differentiate symptoms and signs of PAH from disorders with similar presentations to help improve early referral and recognition of the disease
  • Discuss how to develop a patient-centered, guideline-directed, evidence-based management plan for PAH that includes consideration of novel therapies and current clinical trial data
  • Describe the patient experience for patients with PAH

There are no fees for participating and receiving CME/CE credit for this activity. During the period of May 26, 2021 through May 26, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.




Nurse Practitioner Credit Designation


This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integrity Continuing Education. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.0 contact hour (which includes 0.3 hours of pharmacology).


Accreditation Statement
Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Integrity Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Contact Information
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.

For information about AANP accreditation of this activity, please contact Global Education Group at (303) 395-1782 or cme@globaleducationgroup.com.


Integrity Continuing Education and Global Education Group requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Vallerie V. McLaughlin, MD
Consulting Fees – Acceleron, Actelion, Altavant, Caremark, CiVi Biopharma, Gossamer Bio, Liquidia, United Therapeutics
Contracted Research – Acceleron, Actelion, Gilead, National Institutes of Health (NIH), Sonovie, Reata, United Therapeutics

Martha Kingman, DNP FNP-C
Consulting Fees – Actelion, Bayer, United Therapeutics

The planners and managers, Michelle R. Rizzo, ELS, and Donna Fausak, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. The Global Education Group planners and managers, Kristin Delisi, NP, Lindsay Borvansky, Andrea Funk, Liddy Knight, and Ashley Cann, also have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integrity Continuing Education and Global Education Group do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS

  • Plug-in: Adobe® Flash® Player 10
  • Adobe® Flash® Player 10 plug-in should be downloaded

Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus
For optimal performance, the use of Internet Explorer below 8 is not recommended.

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below
Click here for more information


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of healthcare professionals relative to diagnostic and treatment options of a specific patient’s medical condition.


This activity is supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.


This CME activity is provided by Integrity Continuing Education.

This AANP activity is jointly provided by Global Education Group and Integrity Continuing Education.


Continue to Pretest